ADPTAdaptive Biotechnologies Corporation
$26.49+98% 1Y
$26.49
$12.4152 weeks$29.86
The financials
Adaptive Biotechnologies Corporation by the numbers
Adaptive Biotechnologies Corporation (ADPT) reported revenue of $72M in Q2 2026 (quarter ended Jun 30, 2026), up 22% from the same quarter a year earlier. That came with a gross margin of 72% and net loss of $40M. For the full year FY2025, revenue was $277M (+55% year on year) and net income −$59M. Its largest product in Q2 2026 was Service at $66M, 92% of the disclosed total, well ahead of Service And Licensing at 7.5%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $72M | $59M | +22% |
| Gross profit | $51M | $41M | +26% |
| Operating income | −$16M | −$25M | n/a |
| Net income | −$40M | −$26M | n/a |
| Diluted EPS | −$0.25 | −$0.17 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Service | $66M | 92% |
| Service And Licensing | $5.4M | 7.5% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $71.6M (+0.96%)
Service grew +49% year on yearRegulatory Milestone -100% year on year
Segment Latestquarter on quarteryear on year
- Service$66.2M$66.2Mquarter on quarter +14%year on year +49%+14%+49%
- Service And Licensing$5.4M$5.4Mquarter on quarter +42%year on year +7.7%+42%+7.7%
- Collaboration$0.00$0.00quarter on quarter n/ayear on year -100%n/a-100%
- Regulatory Milestone$0.00$0.00quarter on quarter -100%year on year -100%-100%-100%
Diagnostics & Research
Ranks #13 of 21 by RyuScore